阻断NAT上的潜在代谢部位,以提高其安全性,同时保持药理性
Rachael Flammia1, Boshi Huang1, Piyusha P Pagare1
1Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 E Leigh Street, Richmond, VA 23298, United States.
研究人员开发了新型化合物来治疗阿片类药物使用障碍,旨在改进现有疗法. 化合物12通过保留关键的药理效应,同时减少小鼠的戒断症状,显示出有希望的结果.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿片类药物使用障碍 (OUD) 和过量服用死亡人数急剧增加,需要改进治疗方法.
- 目前FDA批准的OUD疗法具有不良影响,限制了患者的坚持.
- 之前的一种化合物NAT已经证明有效,但对代谢稳定性提出了担忧.
研究的目的:
- 设计和合成新的NAT衍生物来克服代谢负债.
- 评估这些衍生物在片受体中的结构-活性关系.
- 确定一种具有改善OUD治疗潜力的新化学实体.
主要方法:
- 合成了15种NAT衍生物,在烯环的5'-位置进行了修改.
- 评估了片受体的结合亲和力,选择性和功能活性.
- 在活体中评估了对抗吗啡的抗受体作用和减轻阿片类药物依赖小鼠的戒断症状的疗效.
主要成果:
- 化合物12显示保留了与NAT.类似的片受体对抗剂特性.
- 化合物12在临床前模型中表现出更好的戒断效应管理.
- 结构-活动关系研究指导了优化过程.
结论:
- 化合物12是OUD治疗的有希望的新主要候选者.
- 这种衍生品通过解决不良影响,提供了与现有疗法相比的潜在优势.
- 进一步的表征是有必要的,以探索其对OUD管理的全部治疗潜力.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
相关概念视频
Drug Biotransformation: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Prodrugs
Prodrugs help overcome...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
